Skip to content

Arcutis Biotherapeutics, Inc. ARQT Weighted Average Exercise Price of Outstanding Options

Weighted Average Exercise Price of Outstanding Options at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$101.43+24.5%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$18.66+56.0%

Other financials

Income statement

See full
Revenue$105.4M+60.1%
Gross profit$95.6M+67.7%
Operating income-$9.1M+62.9%
Net income-$11.3M+54.9%
EPS (diluted)-$0.09+55.0%

Balance sheet

See full
Cash & equivalents$35.1M-34.7%
Total debt$114.7M+3.5%
Total equity$189.6M+32.9%
Total assets$460.0M+33.7%

Cash flow

See full
Operating cash flow$2.2M+107%
CapEx--100%
Free cash flow$2.2M+107%

Valuation

See full
Market cap$3.29B+57.5%

Profitability

See full
Gross margin90.9%+2.5pp
Operating margin-12%-5.7pp
Net margin-13.9%-6.6pp
FCF margin-52.5%-21.9pp

Returns & leverage

See full
Return on equity-28.2%-13.0pp
Debt / equity0.6×-0.2×
Current ratio2.7×-0.9×

Where this comes from

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arcutis Biotherapeutics, Inc.'s weighted average exercise price of outstanding options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arcutis Biotherapeutics, Inc.'s weighted average exercise price of outstanding options?
Arcutis Biotherapeutics, Inc. (ARQT) reported weighted average exercise price of outstanding options of $12.39 in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s weighted average exercise price of outstanding options changed year-over-year?
Arcutis Biotherapeutics, Inc.'s weighted average exercise price of outstanding options increased by 42.7% year-over-year, from $8.68 to $12.39.
What is the long-term trend for Arcutis Biotherapeutics, Inc.'s weighted average exercise price of outstanding options?
Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s weighted average exercise price of outstanding options has grown at a -5.4% compound annual growth rate (CAGR), from $12.09 to $9.17.
What does weighted average exercise price of outstanding options mean?
This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.